GW Pharmaceuticals PLC's stock spiked at 811p on Sept. 26 – its highest value this year on the London Stock Exchange – following the publication of the third set of positive Phase III data this year for its cannabinoid Epidiolex (cannabidiol) in rare forms of pediatric epilepsy.
The most recent data from a second Phase III study in in patients with Lennox-Gastaut syndrome (LGS), a rare and...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
